Corcept Therapeutics Incorporated. Aktie News

BOSTON, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Corcept Therapeutics Inc. (Nasdaq: CORT) for potential securities law violations. Investors who have lost money in their Corcept Therapeutics investment should contact the firm to learn more about how they might recover those losses.

The chief development officer of Corcept Therapeutics sold 20,000 shares of the biotech for $703,656 on Tuesday. The transaction was executed as a direct open-market sale of option shares; no indirect entities were involved.

SAN FRANCISCO, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) saw the price of their shares crater 50% on December 31, 2025 after the company announced its receipt of a complete response letter (“CRL”) from the FDA for its proposed treatment of patients with hypercortisolism (also known as Cushing's syndrome) – relacorilant.

NEW YORK--(BUSINESS WIRE)-- #investigation--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a shareholder and consumer rights litigation firm, is investigating whether Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ: CORT) or certain of its officers and directors issued misleading and false statements and/or failed to disclose information material to investors in violat...

Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Corcept (CORT) To Contact Him Directly To Discuss Their Options

SAN FRANCISCO, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) saw the price of their shares crater 50% on December 31, 2025 after the company announced its receipt of a complete response letter (“CRL”) from the FDA for its proposed treatment of patients with hypercortisolism (also known as Cushing's syndrome) – relacorilant. The news and severe m...

SAN FRANCISCO, Jan. 6, 2026 /PRNewswire/ -- Investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) saw the price of their shares crater 50% on December 31, 2025 after the company announced its receipt of a complete response letter ("CRL") from the FDA for its proposed treatment of patients with hypercortisolism (also known as Cushing's syndrome) – relacorilant. The news and severe market...

Corcept Therapeutics (CORT) leverages Korlym's commercial success in hypercortisolism, generating $559.3M in nine-month 2025 revenue and $19M Q3 net income. Despite positive Phase 3 data, the FDA unexpectedly rejected CORT's NDA for Relacorilant, citing insufficient benefit-risk evidence. Korlym's ongoing revenues provide a valuation floor and financial support for further Relacorilant trials.